Third annual forum on T-cell lymphoma.

Abstract

The Third Annual T-cell Lymphoma Forum, held on 27-29 January 2011 in San Francisco (CA, USA), continued in the spirit of the two earlier conferences and provided a collegial venue for clinicians and scientists to discuss advances in the science and treatment of T-cell lymphomas. More than 40 experts from around the world presented updates on classification, epidemiology and prognosis; rare and T-cell lymphomas of unspecified origin, CD30(+) T-cell lymphomas; new treatment strategies; new agents and rational combinations; and transplantation. Of particular interest this year was a discussion on the link between breast implants and anaplastic large-cell lymphoma, which coincided with the US FDA announcement of this rare but noteworthy relationship. Submitted abstracts and poster presentations rounded off each of the sessions.

• Authors: Kensei Tobinai
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 11 Issue 5 Pg. 693-5 (May 2011) ISSN: 1744-8328 [Electronic] England
• PMID: 21554042 (Publication Type: Congress)

Chemical References

• Antineoplastic Agents
• Ki-1 Antigen

Topics

• Antineoplastic Agents (therapeutic use)
• Breast Implants (adverse effects)
• Combined Modality Therapy
• Humans
• Ki-1 Antigen (metabolism)
• Lymphoma, Large-Cell, Anaplastic (etiology)
• Lymphoma, T-Cell (epidemiology, pathology, therapy)
• Prognosis